This afternoon we watched Alkermes rise 4.6% to a price of $28.57 per share. The mid-cap Pharmaceutical company is now trading -13.67% below its average target price of $33.09. Analysts have set target prices ranging from $25.0 to $42.0 per share for Alkermes, and have given the stock an average rating of buy.
The stock has an above average percentage of its shares sold short at 8.0%, and a short ratio of 7.91. Since 1.29% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 106.9% of Alkermes's shares being owned by this investor type.
Institutions Invested in Alkermes
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-09-30 | Vanguard Group Inc | 11% | 18,667,269 | $533,230,548 |
| 2023-09-30 | Blackrock Inc. | 10% | 17,161,257 | $490,211,315 |
| 2023-09-30 | Wellington Management Group, LLP | 7% | 11,746,792 | $335,547,119 |
| 2023-09-30 | Sarissa Capital Management, LP | 4% | 7,042,200 | $201,160,446 |
| 2023-09-30 | Renaissance Technologies, LLC | 4% | 6,116,013 | $174,703,914 |
| 2023-09-30 | State Street Corporation | 4% | 6,091,494 | $174,003,529 |
| 2023-09-30 | Pictet Asset Management Holding SA | 3% | 5,484,028 | $156,651,262 |
| 2023-12-31 | Hardman Johnston Global Advisors LLC | 3% | 5,476,255 | $156,429,226 |
| 2023-09-30 | Deep Track Capital, Lp | 2% | 3,800,000 | $108,547,002 |
| 2023-12-31 | Primecap Management Company | 2% | 3,565,625 | $101,852,080 |
Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on Alkermes.
